# US 2004/0082604 A1 · Thiazole and imidazo (4,5-B) pyridine compounds and their pharmaceutical use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082604 A1
- Document ID: US20040082604A1
- Status: Published application
- Kind: A1
- Application number: 10/601,690
- Filed: 2003-06-23
- Published: 2004-04-29
- Earliest claimed: 1999-10-27
- Assignees: Novartis AG
- Inventors: Laszlo Revesz
- Web page: https://patentgrep.com/patent/US20040082604A1

## CPC

- C07D 417/14: containing three or more hetero rings
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4436: containing a heterocyclic ring having sulfur as a ring hetero atom
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07D 471/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of formula (I) 1 and pharmaceutically-acceptable and pharmaceutically-acceptable and -cleavable esters thereof and acid addition salts thereof, wherein the symbols are as defined are MAP kinase inhibitors, useful pharmaceutically for treating TNFα and IL-1 mediated diseases such as rheumatoid arthritis and diseases of bone metabolism, e.g. osteoporosis.

## Claims

### Claim 1

A compound of formula I
83
wherein Nu is a heterocyclic nucleus selected from thiazole in which the R1, R2 and R3 substituents are disposed as indicated below
84
or imidazo[4,5-b]pyridine in which the R1, R2 and R3 substituents are disposed as indicated below
85
wherein
R1 is pyrimidyl or pyridyl;
X is —NR6—Y—, —O— or —S—,
where R6 is H, C1-C4alkyl, C3-C8cycloalkyl, C3-C8cycloalkylC1C3alkyl, C6-C18aryl, C3-C18heteroaryl, C7-C19aralkyl or C4-C19heteroaralkyl, and —Y— is C1-C4alkylene or a direct bond;
R2 is phenyl, optionally substituted by one or more substituents, each of which is independently selected from
halo,
CF3,
cyano,
amido or thioamido which is optionally mono- or di-N-substituted by C1-C4alkyl or the N atom of which forms a 5-7 membered heterocyclic ring optionally containing an additional hetero atom selected from O, S or N which N is optionally C—C4alkyl C1-C4alkylcarbonyl or C1-C4alkylthiocarbonyl substitued,
carboxylate or thiocarboxylate optionally in the form of an optionally halo-substituted C1-C10alkoxy, C2-C10alkenoxy, C2-C10alkynoxy, C3-C7cyclalkoxy, C5-C7cycloalkenoxy, aryloxy, arylalkoxy, heteroaryloxy or heteroarylalkoxy ester,
optionally mono- or di-C1-C4alkyl-substituted-C0-C1alkyl optionally C1-C4alkyl- or C3-C5 cycloalkyl-substituted-carbonyl or -thiocarbonyl,
optionally halo-substituted-C1-C4alkoxy, C2-C4alkenoxy, C2C4alkynoxy, C3-C5cycloalkoxy or C3-C5cyclothioalkoxy,
optionally halo substituted C1-C4 alkyl,
oxycarbonyl or optionally N—C1-C4alkyl-substituted aminocarbonyl both of which are optionally C1-C4alkyl or C3-C5cycloalkyl substituted (including thiocarbonyl analogues thereof),
optionally mono- or di-C1-C4alkyl-substituted-C0C1alkylamine which is optionally mono-or di-N—C1-C4 alkyl substituted,
optionally mono- or di-C1-C4alkyl-substituted-C0-C1alkyl optionally N—C1-C4alkyl-substituted amino-carbonyl or -thiocarbonyl,
optionally N—C1-C4alkyl-substituted amino-sulphinyl or -sulphonyl optionally substituted by
optionally mono- or di-N—C1-C4alkyl-substituted amino,
a nitrogen atom which form a heterocyclic ring of 5 to 7 members optionally containing an additional heteroatom selected from O, S or N which N is optionally C1-C4alkyl C1-C4alkylcarbonyl or C1-C4alkylthiocarbonyl substitued, or
sulphinyl or sulphonyl optionally substituted by
optionally halo-substituted-C1-C4alkyl, C2-C4 alkenyl, C2-C4 alkynyl,
optionally mono- or di-C1-C4alkyl-substituted amino,
a nitrogen atom which form a heterocyclic ring of 5 to 7 members optionally containing an additional heteroatom selected from O, S or N which N is optionally C1-C4alkyl C1-C4alkylcarbonyl or C1-C4alkylthiocarbonyl substitued;
R3 is H, amino, C1-C10alkyl, C3-C10cycloalkyl, C3-C18heterocycloalkyl, C6-C18aryl, or C3-C18heteroaryl each of which is optionally substituted by up to 4 substituents separately selected from C1-C4alkyl, halogen, halo-substitued-C1-C4alkyl, hydroxy, C1-C4alkoxy, C1-C4alkylthio, C6-C18aryl, C3-C18heteroaryl, C6-C18arylC1-C4alkyl, C3-C18 heteroarylC1-C4alkyl, C3-C18heterocycloalkyl or optionally mono- or di-C1-C4alkyl substituted amino or by N-heterocyclyl containing from 5 to 7 ring atoms and optionally a further hetero atom selected from O, S or N, all of which are further optionally substituted halo, hydroxy, C1-C4alkyl, C1-C4alkoxy or C1-C4alkoxycarbonyl;
R4 is C1-C10alkyl, C6-C18aryl C3-C18heteroaryl, or C3-C12cycloalkyl optionally substituted by up to 3 substituents separately selected from C1-C4alkyl, halogen, halo-substitued- C1-C4alkyl hydroxy, C1-C4alkoxy, C1-C4alkylthio, optionally mono- or di-C1-C4alkyl substituted amino, or by N-heterocyclyl containing from 5 to 7 ring atoms and optionally containing a further hetero atom selected from O, S or N,
and pharmaceutically-acceptable and -cleavable esters thereof and acid addition salts thereof

### Claim 2 (depends on 1)

A compound according to claim 1 of formula II
86
wherein
Z is N or CH;
X is —NR6—Y—, —O— or —S—,
where R6 is H, C1-C4alkyl, C3-C8cycloalkyl, C3-C8cycloalkylC1-C3alkyl, C6-C18aryl, C3-C18heteroaryl, C7-C19aralkyl or C4-C19heteroaralkyl, and —Y— is C1-C4alkylene or a direct bond;
R2′ is phenyl, optionally substituted by one or more substituents, each of which is independently selected from halo, CF3, cyano, amido or thioamido, carboxylate or thiocarboxylate, C1-C4alkoxy, C1-C4alkyl, or NH2 which is optionally mono-or di-C1-C4 alkyl substituted;
R3′ is H, C1-C10alkyl, C3-C10cycloalkyl, C3-C18heterocycloalkyl, C6-C18aryl or C3-C18heteroaryl each of which is optionally substituted by up to 4 substituents separately selected from C1-C4alkyl, halogen, halo-substitued-C1-C4alkyl, hydroxy, C1-C4alkoxy, C1-C4alkylthio, or optionally mono-or di-C1-C4alkyl substituted amino, or by N-heterocyclyl containing from 5 to 7 ring atoms and optionally containing a further hetero atom selected from O, S or N;
R4′ is C6-C18aryl, C3-C18heteroaryl, or C3-C12cycloalkyl each of which is optionally substituted by up to 4 substituents separately selected from C1-4alkyl, halogen, halo-substitued-C1-4alkyl, hydroxy, C1-4alkoxy, C1-4alkylthio, or optionally mono-or di-C1-4alkyl substituted amino, or by N-heterocyclyl containing from 5 to 7 ring atoms and optionally containing a further hetero atom selected from O, S or N,
and pharmaceutically-acceptable and -cleavable esters thereof and acid addition salts thereof.

### Claim 3 (depends on 2)

A compound according to claim 2 of formula II′
87
wherein
R4″ is phenyl or C3-C7cycloalkyl each of which is optionally mono-substituted by halogen,
C1-C4allyl, C1-C4alkoxy, hydroxy, trihalomethyl or optionally mono-or di-C1-C4alkyl substituted amino, or by N-heterocyclyl containing from 5 to 7 ring atoms and optionally containing a further hetero atom selected from O, S or N;
R10 is halogen, cyano, amido, thioamido, amino or C1-C4alkyl;
R3″ is H, C1-C4alkyl, phenyl, pyridyl, morpholinyl, piperidyl, piperazyl, or optionally mono- or di-C1-4alkyl substituted amino, each of which is optionally substituted, e.g. by up to 2 substituents, separately selected from C1-C4alkyl, halogen, hydroxy, C1-C4alkoxy, or optionally mono-or di-C1-C4alkyl substituted amino;
Z is N or CH and
X″ is —NH—Y′—, —O— or —S—, where Y′ is —CH2—, —CH2—CH2—, —CH(CH3)— or a direct bond,
and pharmaceutically-acceptable and -cleavable esters thereof and acid addition salts thereof.

### Claim 4 (depends on 2)

A compound according to claim 2 selected from:
4-(4-Fluorophenyl)-5-(2-[1-(S)-phenylethyl]amino-4-pyrimidinyl)-2-(4methyl-piperidine-1-yl)thiazole;
4(4-Fluorophenyl)-5-(2-[1-(S)-phenylethyl]amino-4-pyrimidinyl)-2-(4-NH-piperidine-1-yl)thiazole;
4-(4-Fluorophenyl)-2-(4-methylpiperidine-1-yl)-5-(2-[cyclopropyl-methyl]amino-4-pyridinyl)thiazole and
4-(4-Fluorophenyl)-2-(4-NH-piperidine-1-yl)-5-(2-(1-(S)-phenylethyl)amino-4-pyridinyl)thiazole;
and pharmaceutically-acceptable and -cleavable esters thereof and acid addition salts thereof.

### Claim 5 (depends on 3)

A process for the preparation of a compound of formula II″
88
wherein R3″, R4″, R10 and Z are as defined in claim 3 and X′″ is —NH—, which comprises reacting the corresponding precursor compound of formula III or III′
89
with the corresponding R4″-NH2 amine, wherein R3″, R4″ and R10 are as defined in claim 3, and thereafter, if desired, converting the compound of formula II″ obtained into a further compound of formula II″ or a pharmaceutically-acceptable and cleavable ester thereof or acid addition salt thereof.

### Claim 6 (depends on 1)

A compound according to claim 1 of formula V
90
wherein
R1 is pyrimidyl;
X is —NP6—Y—, —O— or —S—,
where R6 is H, C1-C4alkyl, C6-C18aryl, C3-C18heteroaryl, C7-C19aralkyl or C4-C19heteroaralkyl, and —Y— is C1-C4alkylene or a direct bond;
R12 is phenyl, optionally substituted by one or more substituents, each of which is independently selected from
halo,
CF3,
cyano,
amido or thioamido which is optionally mono- or di-N-substituted by C1-C4alkyl or the N atom of which forms a 5-7 membered heterocyclic ring optionally containing an additional hetero atom selected from O, S or N which N is optionally C1-C4alkyl C1-C4alkylcarbonyl or C1-C4alkylthiocarbonyl substitued,
carboxylate or thiocarboxylate optionally in the form of an optionally halo- substituted C1-C10alkoxy, C2-C10alkenoxy, C2-C10alkynoxy, C3-C7cyclalkoxy, C5-C7cycloalkenoxy, aryloxy, arylalkoxy, heteroaryloxy or heteroarylalkoxy ester,
optionally mono- or di-C1-C4alkyl-substituted-C1-C4alkyl optionally C1-C4alkyl- or C3-C5cycloalkyl-substituted-carbonyl or -thiocarbonyl
optionally halo-substituted-C1-C4alkoxy, C2-Calkenoxy, C2-C10alkynoxy, C3-C5cycloalkoxy or C3-C5cyclothioalkoxy,
optionally halo substituted C1-C4 alkyl,
oxycarbonyl or optionally N—C1-C4alkyl-substituted aminocarbonyl both of which are optionally C1-C4alkyl or C3-C5cycloalkyl substituted (including thiocarbonyl analogues thereof),
optionally mono- or di-C1-C4alkyl-substituted-C0-C1alkylamine which is optionally mono-or di-N—C1-C4 alkyl substituted,
optionally mono- or di-C1-C4alkyl-substituted-C0-C1alkyl optionally N—C1-C4alkyl-substituted amino-carbonyl or -thiocarbonyl,
optionally N—C1-C4alkyl-substituted amino-sulphinyl or -sulphonyl optionally substituted by
optionally mono- or di-N—C1-C4alkyl-substituted amino,
a nitrogen atom which form a heterocyclic ring of 5 to 7 members optionally containing an additional heteroatom selected from O, S or N which N is optionally C1-C4alkyl C1-C4alkylcarbonyl or C1-C4alkylthiocarbonyl substituted, or
sulphinyl or sulphonyl optionally substituted by
optionally halo-substituted-C1-C4alkyl, C2-C4 alkenyl, C2-C4 alkynyl,
optionally mono- or di-N—C1-C4alkyl-substituted amino,
a nitrogen atom which form a heterocyclic ring of 5 to 7 members optionally containing an additional heteroatom selected from O, S or N which N is optionally C1-C4alkyl C1-C4alkylcarbonyl or C1-C4alkylthiocarbonyl substitued;
R13 is H. amino, C1-C10alkyl, C3-C10cycloalkyl, C3-C18heterocycloalkyl, C6-C18aryl, or C3-C18heteroaryl all optionally substituted by up to 4 substituents separately selected from C1-C4alkyl, halogen, halo-substitued-C1-C4alkyl, hydroxy, C1-C4alkoxy, C1-C4alkylthio, C6-C18aryl, C3-C18heteroaryl, C6-C18aryl C1-C4alkyl), C3-C18heteroarylC1-C4alkyl C3-C18heterocycloalkyl or optionally mono- or di-N—C1-C4alkyl substituted amino all of which are optionally substituted by halo, hydroxy, C1-C4alkyl, C1-C4alkoxy or C1-C4alkoxycarbonyl;
R14 is C1-C10alkyl, C6-C10aryl, C3-C18heteroaryl, or C3-C12cycloalkyl optionally substituted by up to 3 substituents separately selected from C1-C4alkyl, halogen, halo-substitued-C1-C4alkyl, hydroxy, C1-C4alkoxy, C1-C4alkylthio, optionally mono- or di-N—C1-C4alkyl substituted amino, or by N-heterocyclyl containing from 5 to 7 ring atoms and optionally containing a further hetero atom selected from O, S or N,
and pharmaceutically-acceptable and -cleavable esters thereof and acid addition salts thereof.

### Claim 7 (depends on 6)

A compound according to claim 6 of formula V′
91
wherein,
R14′ is phenyl or C3-C7cycloalkyl each of which is optionally mono-substituted by halogen, C1-C4alkyl, C1-C4alkoxy, hydroxy, trihalomethyl optionally mono- or di-N—C1-C4alkyl substituted amino, or by N-heterocyclyl containing from 5 to 7 ring atoms and optionally containing a further hetero atom selected from O, S or N;
R10 is halogen, CF3, C1-C4alkyl or C1-C4alkoxy;
R13′ is pyridyl, pyrimidyl, piperazinyl, piperidinyl, NR9R10, —CH2OH, CH2NR15R16, —CH2CH2R15R16, or Het-C1-C4alkyl-,
wherein
R9p and R10 are separately selected from H, C1-C4alkyl, C6-C18aryl, C3-C18 heteroaryl,
C6-C18arylC1-C4alkyl, C3-C18heteroarylC1-C4alkyl all of which are optionally substituted by halo, hydroxy, C1-C4alkyl, C1-C4alkoxy, C1-C4alkoxycarbonyl,
R11 and R12 are separately selected from H or C1-C6alkyl, and
Het is N-heterocyclyl containing from 5 to 0.7 ring atom and optionally containing a further heteroatom(e.g. O, S or N)
X″ is —NH—Y′—, —O— or —S—, where Y′ is —CH2—, —CH2—CH2—, —CH(CH3)— or a direct bond,
and pharmaceutically-acceptable and -cleavable esters thereof and acid addition salts thereof.

### Claim 8 (depends on 6)

A compound according to claim 6 selected from:
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(piperidino-N-2-ethyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(N,N-diethylamino-N-2-ethyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(morpholino-N-2-ethyl)ibidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(isopropylamino-N-2-ethyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(pyrrolidino-N-2-ethyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(3-pyridyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(4-pyridyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)- 1-(2-(1-(S)-phenylethyl)amino-4-pyrimidinyl)-5-aminoimidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(pyrrolidino-N-2-ethyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-(1-(S)-phenylethyl)amino-4-pyridinyl)-5-(4-NH-1-piperazinyl) imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(4NH-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclobutylamino-4-pyrimidinyl)-5-(4-NH-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopropylamino-4pyrimidinyl)-5-(4NH-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-(1-(S)-phenylethyl)amino pyrimidinyl)-5-(4-methyl-1-piperazinyl) imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylaminopyrimidinyl)-5-(4-methyl-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclobutylamino-4-pyrimidinyl)-5-(methyl-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)- 1-(2-cyclopropylamino-4-pyrimidinyl)-5-(4-methyl-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-(1-(S)-phenylethyl)amino-4-pyrimidinyl)-5-(4-(2-hydroxy-2-methyl)propyl-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(4-(2-hydroxy-2-methyl)propyl-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4Fluorophenyl)-1-(2-cyclobutylamino-4-pyrimidinyl)-5-(4-(2-hydroxy-2-methyl)propyl-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopropylamino-4-pyrimidinyl)-5-(4-(2-hydroxy-2-methyl)propyl-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(4-piperidinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(1-methyl-4-piperidinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(1-(2-hydroxy-2-methyl)propyl-4-piperidinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(benzylamino)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(morpholino)imidazo[4,5-b]pyridine;
2-(4Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(3-fluorophenyl amino)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(pyridyl-4-amino)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(1 ethoxycarbonyl piperidine-4-amino)imidazo[4,5-b]pyridine, and
2-(4Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(piperidine-4-amino)imidazo[4,5b]pyridine.

### Claim 9

A process for the production of
(i) an Agent of the Invention of formula V″
92
wherein R11, R12, R14 and X are as previously defined and R13″ is —CH2—CH2NR15R16 or —CH2—CH2-Het wherein R15, R16 and Het are as previously defined comprising reacting a corresponding vinyl precursor of formula VI
93
wherein R11, R12, R14 and X are as previously defined with the corresponding amine of formula HNR15R16, or N-heterocycloalkyl ring compound;
(ii) an Agent of the Invention of formula V wherein R13 is aryl or heteroaryl comprising arylation or heteroarylation of a compound of formula VII
94
wherein R11, R12, R14 and X are as previously defined;
(iii) an Agent of the Invention of formula V wherein R13 is —N-heterocycloalkyl, —NH-aryl, —NH—heteroaryl, —NH-heterocycloalkyl, —NH—(C1-C4alkyl)-heterocycloalkyl, —NH—(C1-C4alkyl)-aryl, —NH—(C1-C4alkyl)-heteroaryl, or —NH—(C1-4alkyl)-heterocycloalkyl comprising coupling a corresponding chloroprecursor compound of formula VII, as defined above, with the corresponding N-heterocycloalkyl compound or amine;
(iv) an Agent of the Invention of formula V in which R13 is —NH2, comprising reacting the corresponding methyl sulphinyl compound of formula VIII′
95
wherein R11, and R12 are as previously defined, with the corresponding amine of formula R14—NH2, and
(v) an Agent of the Invention of formula V in which R13 is piperazinyl, comprising reacting a corresponding methylsulphinyl compound of formula VIII′
96
wherein R1, and R12 are as previously defined and P is an N protecting group, with the corresponding amine of formula R14—NH2.

### Claim 10 (depends on 1)

A method of inhibiting production of soluble TNF, especially TNFα, or of reducing inflammation in a subject (i.e., a mama especially a human) in need of such treatment which method comprises administering to said subject an effective amount of a compound according to claim 1.

### Claim 11 (depends on 1)

A compound according to claim 1 for use as a pharmaceutical, e.g. for use as an immunosuppressant or antiinflammatory agent or for use in the prevention, amelioration or treatment of any disease or condition as described above, e.g., an autoimmune or inflammatory disease or condition.

### Claim 12 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 in association with a pharmaceutically acceptable diluent or carrier, e.g., for use as an immunosuppressant or anti-inflammatory agent or for use in the prevention, amelioration or treatment of any disease or condition as described above, e.g., an autoimmune or inflammatory disease or condition.

### Claim 13 (depends on 1)

Use of a compound according to claim 1 in the manufacture of a medicament for use as an immunosuppressant or anti-inflammatory agent or for use in the prevention, amelioration or treatment of any disease or condition as described above, e.g., an autoimmune or inflammatory disease or condition.
